Insider Buying: RxSight, Inc. (NASDAQ:RXST) Director Acquires $44,992.74 in Stock

RxSight, Inc. (NASDAQ:RXST) Director Jesse Anderson Corley bought 1,443 shares of the business’s stock in a transaction dated Wednesday, January 15th. The stock was bought at an average price of $31.18 per share, for a total transaction of $44,992.74. Following the purchase, the director now owns 1,443 shares in the company, valued at approximately $44,992.74. This represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Jesse Anderson Corley also recently made the following trade(s):

• On Tuesday, November 12th, Jesse Anderson Corley acquired 11,111 shares of RxSight stock. The stock was purchased at an average cost of $45.37 per share, with a total value of $504,106.07.

RxSight Trading Down 2.5 %

Shares of NASDAQ:RXST opened at $30.39 on Monday. The firm’s 50 day moving average is $38.97 and its two-hundred day moving average is $46.62. The firm has a market capitalization of $1.22 billion, a P/E ratio of -36.61 and a beta of 1.20. RxSight, Inc. has a 52 week low of $26.29 and a 52 week high of $66.54.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Wells Fargo & Company decreased their target price on RxSight from $42.00 to $40.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. Stifel Nicolaus lowered their target price on shares of RxSight from $40.00 to $35.00 and set a “hold” rating for the company in a research note on Monday, January 13th. UBS Group initiated coverage on shares of RxSight in a research report on Friday, December 6th. They issued a “buy” rating and a $52.00 price target on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $66.00 price objective on shares of RxSight in a research report on Monday, January 13th. Finally, Jefferies Financial Group began coverage on shares of RxSight in a report on Tuesday, October 29th. They issued a “buy” rating and a $72.00 target price on the stock. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $58.13.

Institutional Trading of RxSight

Several large investors have recently added to or reduced their stakes in RXST. Nisa Investment Advisors LLC grew its stake in shares of RxSight by 854.1% in the third quarter. Nisa Investment Advisors LLC now owns 582 shares of the company’s stock worth $29,000 after purchasing an additional 521 shares in the last quarter. Quarry LP lifted its holdings in RxSight by 82.3% in the third quarter. Quarry LP now owns 638 shares of the company’s stock worth $32,000 after purchasing an additional 288 shares during the period. Point72 Hong Kong Ltd bought a new position in RxSight in the 3rd quarter valued at about $34,000. Quest Partners LLC acquired a new position in RxSight during the 2nd quarter valued at about $41,000. Finally, Harbor Investment Advisory LLC bought a new stake in shares of RxSight during the 4th quarter worth about $52,000. 78.78% of the stock is currently owned by institutional investors and hedge funds.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.